Australia Cell and Gene Therapy Market

Australia Cell and Gene Therapy Market Overview:

The Australia cell and gene therapy market size reached USD 425.60 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,995.47 Million by 2033, exhibiting a growth rate (CAGR) of 18.73% during 2025-2033. The market is growing due to increased government funding, cross-border collaborations, and rising clinical trial activity. Support for early-stage innovation and advanced manufacturing is driving the development of treatments targeting rare diseases and regenerative health conditions.

Australia Cell and Gene Therapy Market Trends:

Focus on Regenerative Treatment Innovation

Australia’s cell and gene therapy market is witnessing a clear shift toward regenerative solutions, particularly in addressing conditions with limited treatment options. The country is actively supporting startups that focus on breakthrough applications capable of restoring or significantly improving bodily functions. The government’s emphasis on commercialization has created an environment where scientific research transitions into real-world impact. The emphasis on vision restoration, neurological repair, and immune modulation showcases a wider trend of targeting irreversible conditions with gene-modifying approaches. In December 2024, the Australian Government allocated USD 2 Million to Mirugen Pty Ltd under the CUREator+ program. The funding was aimed at advancing a gene therapy designed to regenerate cells in the eye and help restore vision, marking a significant step toward treating certain forms of blindness. This development reflected Australia’s commitment to strengthening its regenerative medicine capabilities and building a pipeline of therapies with long-term curative potential. Such projects are not only pushing innovation forward but also encouraging private-sector participation in early-stage development. The growing investment in targeted regenerative technologies indicates that Australia is aligning its healthcare objectives with next-generation biological tools, encouraging the growth of a competitive and forward-looking cell and gene therapy industry.

Expansion of Clinical Manufacturing Capacity

As clinical activity grows across global markets, Australia is increasingly being integrated into multinational therapeutic development programs, especially those requiring advanced production capabilities. Companies are now looking beyond domestic boundaries to establish scalable manufacturing systems that can support trials and prepare for commercial supply. This trend shows Australia’s strategic importance in contributing to global development chains while simultaneously benefiting from expanded access to novel therapies. In April 2025, INmune Bio partnered with the UK-based Cell and Gene Therapy Catapult to scale up the production of CORDStrom, a therapy for the rare genetic skin condition RDEB. The expanded manufacturing support also covered clinical trials across Australia, positioning the country as a key node in the broader commercialization pathway. The collaboration emphasized cross-border infrastructure sharing and highlighted Australia’s role in global therapeutic development. By enabling trial-readiness and securing stable supply chains for advanced therapies, the local market benefits from accelerated timelines and improved patient access. This trend indicates rising confidence in Australia’s clinical ecosystem and its ability to handle complex biologics manufacturing as part of multinational programs.

Australia Cell and Gene Therapy Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on therapy type, indication, delivery mode, and end user.

Therapy Type Insights:

• Cell Therapy
  • Stem Cell
    • Pluripotent Stem Cell
    • Cancer Stem Cell
    • Adult Stem Cell
  • Non-Stem Cell
    • T Cells
    • Natural Killer
    • Others
• Gene Therapy

The report has provided a detailed breakup and analysis of the market based on the therapy type. This includes cell therapy {stem cell (pluripotent stem cell, cancer stem cell, and adult stem cell) non-stem cell (T cells, natural killer, and others)} and gene therapy.

Indication Insights:

• Cardiovascular Disease
• Oncology Disorder
• Genetic Disorder
• Infectious Disease
• Neurological Disorder
• Others

A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes cardiovascular disease, oncology disorder, genetic disorder, infectious disease, neurological disorder, and others.

Delivery Mode Insights:

• In-Vivo
• Ex-Vivo

A detailed breakup and analysis of the market based on the delivery mode have also been provided in the report. This includes in-vivo and ex-vivo.

End User Insights:

• Hospitals
• Cancer Care Centers
• Pharmaceutical & Biotechnology Companies
• Others

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals, cancer care centers, pharmaceutical & biotechnology companies, and others.

Regional Insights:

• Australia Capital Territory & New South Wales
• Victoria & Tasmania
• Queensland
• Northern Territory & Southern Australia
• Western Australia 

The report has also provided a comprehensive analysis of all the major regional markets, which include Australia Capital Territory & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, and Western Australia.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Australia Cell and Gene Therapy Market News:

• April 2025: INmune Bio partnered with CGT Catapult to scale up CORDStrom manufacturing, supporting trials across Australia and other regions. This development strengthened Australia’s cell and gene therapy market by enhancing access to advanced treatments for rare genetic diseases like RDEB through global collaboration.
• March 2025: Xcellbio partnered with Planet Innovation to support rapid cell therapy manufacturing using the AVATAR Foundry platform. Its first clinical use at Royal Perth Hospital aimed to enhance TIL therapy potency, strengthening Australia's cell and gene therapy market with advanced, efficient treatment solutions.

Key Questions Answered in This Report:

• How has the Australia cell and gene therapy market performed so far and how will it perform in the coming years?
• What is the breakup of the Australia cell and gene therapy market on the basis of therapy type?
• What is the breakup of the Australia cell and gene therapy market on the basis of indication?
• What is the breakup of the Australia cell and gene therapy market on the basis of delivery mode?
• What is the breakup of the Australia cell and gene therapy market on the basis of end user?
• What is the breakup of the Australia cell and gene therapy market on the basis of region?
• What are the various stages in the value chain of the Australia cell and gene therapy market? 
• What are the key driving factors and challenges in the Australia cell and gene therapy market?
• What is the structure of the Australia cell and gene therapy market and who are the key players?
• What is the degree of competition in the Australia cell and gene therapy market? 

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Australia cell and gene therapy market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the Australia cell and gene therapy market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Australia cell and gene therapy industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.